Aquestive Therapeutics, Inc. (AQST) Q2 2022 Earnings Call Transcript
AQST Stock ,Welcome everyone to Aquestive Therapeutics second quarter 2022 conference call. (Operator instructions) I’d now like to introduce the presenter for the conference call today, Bennett Watson of ICR Westwicke investor relations.
A explanation of these measures, as well as an explanation of the reconciliation to GAAP , is included in the earnings announcement that was released on the same day, and can be found on the Investors section of the website of Aquestive. During the conference call the company will make forward-looking statements. We remind that the company has a safe harbor provisions as stated in the earnings announcement of yesterday and also the uncertainties and risks that affect the company as outlined in the section on risk factors as well as other sections in the annual reports on Form 10K that we filed with the Securities and Exchange Commission on March 8 2022 as well as within our quarterly reports on Form 10Q and the most recent reports on Form 8-K submitted to the SEC. Like any pharmaceutical company with product candidates in development, and products that are being made available for commercialization there are significant risks and uncertainties related to the business of the company as well as the creation, approval from regulatory agencies as well as the commercialization and distribution of product and other aspects of the company’s operations.
The effect of the ongoing COVID-19 pandemic is extremely uncertain and is not able to be predicted with any certainty or clarity. Because of this it is not advisable to put too much faith in these forward-looking statements that are only based on the date they were made. Actual results could differ significantly from the statements. Forward-looking statements that are made by Aquestive or anyone acting on its behalf is specifically qualified by this cautionary note.
Aquestive Therapeutics Returns in comparison to. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| AQST | -66.01% | -95% | ||
| S&P | -7.62% | +49.76% | +8.40% | +45% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $18.65M | -40.2% |
| Accounts Receivable | $8.59M | -22.0% |
| Inventory | 6.725 | +134.9% |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $103.32M | +13.0% |
| Short Term Debt | $16.98M | +62.8% |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -121.2% | +13.2% |
| Return On Invested Capital | -134.3% | +38.4% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | $2.59M | – |
| Operating Free Cash Flow | $2.81M | – |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | -2.58 | -1.31 | -0.29 | -0.65 | -79.3% |
| Price to Sales | 3.09 | 2.08 | 0.58 | 1.30 | -64.3% |
| Price to Tangible Book Value | -2.58 | -1.31 | -0.29 | -0.65 | -79.3% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -22.47 | -23.58 | -10.80 | -19.88 | -40.5% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | – | – | – | – | – |
| Total Debt | $116.71M | $118.96M | $119.27M | $120.30M | +18.1% |
